Evropska unija - slovenščina - EMA (European Medicines Agency)

almirall, s.a. - lebrikizumab - dermatitis, atopic - drugi dermatološki preparati - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.